Connect Biopharm LLC

Connect Biopharma (Connect Biopharm LLC) is a global, clinical-stage biopharmaceutical company headquartered in San Diego, California, with operations in both the United States and China. According to its official website, the company is focused on developing innovative therapies that treat inflammatory diseases, with the stated goal of improving the lives of millions of people affected by such conditions around the world. Its corporate positioning is built around "next-generation therapeutics for inflammatory diseases." The company's lead product candidate is rademikibart, formerly known as CBP-201. Rademikibart is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), a validated pathway in type 2 inflammatory conditions. Connect Biopharma reports that rademikibart has demonstrated activity in both atopic dermatitis and asthma, two major inflammatory disease indications. The company has advanced rademikibart into global clinical development, including a global Phase 2 study evaluating it as an add-on treatment for acute exacerbations in adult and adolescent participants. Connect Biopharma operates as a cross-border organization, combining a U.S. headquarters in San Diego with operations in China. This dual footprint supports clinical development and potential commercialization across both markets. The company communicates with investors and the broader biopharma community through regular financial reporting and conference presentations, including participation in the H.C. Wainwright Annual Global Investment Conference and quarterly business updates. As a clinical-stage company, Connect Biopharma's value proposition centers on its pipeline of inflammatory disease therapies rather than marketed products. Its public communications emphasize clinical milestones, such as the positive preliminary topline data from its global Phase 2 study of rademikibart, alongside financial results and business updates. The company's focus on IL-4Rα-targeting antibodies places it in the competitive landscape of biologics for atopic dermatitis, asthma, and related type 2 inflammatory diseases.

Connect Biopharma is a clinical-stage biopharmaceutical company that has built its identity around the development of therapies for inflammatory diseases. The company is headquartered in San Diego, California, and maintains operations in both the United States and China, reflecting a cross-border operating model that combines a U.S. corporate base with a significant presence in the Chinese biopharma market. The company's central scientific focus is on interleukin-4 receptor alpha (IL-4Rα), a target that plays a key role in type 2 inflammatory signaling. Its lead product candidate, rademikibart (originally designated CBP-201), is an antibody designed to bind IL-4Rα. Connect Biopharma has reported that rademikibart demonstrated activity in atopic dermatitis and asthma, two conditions with substantial patient populations and significant unmet need. Over time, Connect Biopharma has advanced rademikibart through clinical development, including a global Phase 2 study evaluating the candidate as an add-on treatment for acute exacerbations in adult and adolescent participants. In September 2026, the company announced positive preliminary topline data from that study, a key clinical milestone. The company also regularly reports financial results and provides business updates, and it engages with the investment community through conferences such as the H.C. Wainwright Annual Global Investment Conference. As a clinical-stage enterprise, Connect Biopharma does not yet market commercial products; its activities center on research, clinical trials, regulatory interactions, and corporate development. Its public communications emphasize its pipeline, its global clinical footprint, and its aspiration to improve patients' lives through next-generation therapeutics for inflammatory diseases.

• Reported second quarter 2026 financial results and provided a business update.

• Announced participation in the H.C. Wainwright 28th Annual Global Investment Conference.

• Announced positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adult and adolescent participants.

Global, clinical-stage biopharmaceutical company developing next-generation therapeutics for inflammatory diseases.

• Rademikibart (CBP-201)

  An antibody designed to target interleukin-4 receptor alpha (IL-4Rα), with demonstrated activity in atopic dermatitis and asthma.

1. 1Connect Biopharma | Inflammatory Diseases | San Diego, CA, USAconnectbiopharma.com
2. 2About Us | Connect Biopharmaconnectbiopharma.com
3. 3Connect Biopharm LLC (United States) - Wikidatawikidata.org
4. 4Qiming's Portfolio Company Connect Biopharma Lists on Nasdaqprnewswire.com